相关实验视频
Updated: Jun 4, 2025

09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
21.6K
在阿尔茨海默病中视网膜微结构和微血管变化:一篇综述
Marco Antonio Olivares Ordoñez1, Rebekah Cossette Smith1, Glenn Yiu2
1School of Medicine, University of California, Davis, Sacramento, CA.
International ophthalmology clinics
|December 23, 2024
概括
通过OCT和OCTA成像检测到的视网膜生物标志物显示出早期阿尔茨海默病 (AD) 检测的希望. 这些基于眼睛的变化与大脑病理相关,为监测AD进展和治疗疗效提供了一种非侵入性方法.
科学领域:
- 眼科医生 眼科 眼科
- 神经学 神经学
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 在症状出现之前涉及临床前的神经退行.
- 轻度认知障碍 (MCI) 通常在AD之前,共享类似的早期病理变化.
- 视网膜作为中枢神经系统的一部分,可能会表现出与AD相关的病理.
研究的目的:
- 审查阿尔茨海默病和视网膜病理之间的关系.
- 探索光学连贯断层扫描 (OCT) 和OCT血管造影 (OCTA) 在检测这些视网膜变化的有用性.
- 评估视网膜生物标志物的潜力,用于早期AD检测和监测.
主要方法:
- 使用OCT和OCTA对研究阿尔茨海默病视网膜变化的研究进行了综述.
- 视网膜发现与脑成像 (MRI,PET) 和神经心理测试的相关性分析.
- 与AD相关的常见视网膜生物标志物的总结.
主要成果:
- 在阿尔茨海默病患者的常见发现包括视网膜神经纤维层变薄和黄斑厚度降低.
- 观察到,视网膜毛细血管结合体中的毛细血管区域扩大和血管密度降低.
- 视网膜变化与大脑缩,粉样蛋白负载和认知衰退相关.
结论:
- 视网膜微结构和微血管异常显示出早期AD检测生物标志物的潜力.
- 使用OCT和OCTA的眼科成像可以帮助临床监测AD.
- 在AD和MCI研究中需要用于体内眼科成像的标准化方案.
更多相关视频
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
10.5K
10:11Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
Published on: October 22, 2014
19.1K
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162